US Department of Health and Human Services and SAMHSA's National Clearinghouse For Alcohol and Drug Information DHHS SAMHSA's National Clearinghouse For Alcohol and Drug Information
Photo Of Person One Photo Of Person Two Photo Of Person Three Photo Of Person Four
Drugs
Audiences
Issues
Publications
Newsroom
Calendar
Resources
Research

This Web site is a component of the SAMHSA Health Information Network.

Publications
Publications

Quick Find & Order
Top 50
Pubs in Series
Posters
Videos
Spanish
Drugs
Audiences
Issues

This Web site is a component of the SAMHSA Health Information Network.

  

Pregnant, Substance-Using Women
Treatment Improvement Protocol (TIP) Series 2

Guideline 3 -- Medical Withdrawal From Alcohol 11

It should be assumed that pregnant women who consume over 8 ounces of [absolute] alcohol (1 pint of liquor) daily have developed tolerance.12 However, tolerance may develop at lower levels of consumption in some women and in women using multiple drugs.

The sudden cessation of drinking can result in withdrawal symptoms, some of which may be threatening to the mother and the fetus. It is imperative that medical withdrawal of an alcohol-dependent, pregnant woman be conducted in an inpatient setting and under medical supervision that includes collaboration with an obstetrician. These conditions will ensure

  • Close observation and monitoring of maternal alcohol withdrawal status
  • Continual monitoring of fetal well-being

Most programs choose to treat the pregnant, alcohol-dependent woman with short-acting barbiturates or benzodiazepines. Chlordiazepoxide (Librium) and other benzodiazepines, such as diazepam (Valium) and barbiturates (Phenobarbital, Seconal), are valuable for symptomatic treatment during medical withdrawal from alcohol. They are also potentially teratogenic. Some clinicians, therefore, recommend avoiding their use if at all possible. The risks versus the possible benefits of their use need to be assessed.

Disulfiram (Antabuse) is contraindicated during pregnancy. Its use has been associated with clubfoot, VACTERL syndrome (a pattern of congenital anomalies), and phocomelia of the lower extremities.13 The woman who conceives while taking this drug should receive counseling before deciding to continue the pregnancy.

Symptoms of Alcohol Withdrawal
Early symptoms of alcohol withdrawal generally appear 6 to 48 hours after drinking has stopped but can occur up to 10 days after the last drink. Withdrawal symptoms may include
  • Restlessness
  • Tachycardia
  • Irritability
  • Hypertension
  • Anorexia
  • Insomnia
  • Nausea
  • Nightmares
  • Vomiting
  • Impaired concentration
  • Sweating
  • Impaired memory
  • Tremor
  • Elevated vital signs
More severe symptoms of alcohol withdrawal may include
  • Increased tremulousness
  • Increased agitation
  • Increased sweating
  • Delirium (with confusion, disorientation, impaired memory and judgment)
  • Hallucinations (auditory, visual, or tactile)
  • Delusions (usually paranoid)
  • Grand mal seizures
Note: Withdrawal symptoms do not necessarily progress from mild to severe. In some individuals, a grand mal seizure may be the first sign of withdrawal. Seizures usually occur 12 to 24 hours after cessation or reduction of drinking. One-third of all patients who have seizures develop delirium tremens.

Maternal and Fetal Effects of Alcohol

Alcohol use during pregnancy may be associated with a variety of serious health consequences for the woman, the fetus, and the subsequent infant.

1 Possible maternal complications of excessive alcohol consumption:

  • Nutritional deficiencies
  • Pancreatitis
  • Alcoholic ketoacidosis
  • Precipitate labor
  • Alcoholic hepatitis
  • Deficient milk ejection
  • Cirrhosis

2 Possible effects on the fetus:

  • Fetal Alcohol Syndrome (FAS)
    • prenatal/postnatal growth retardation
    • central nervous system deficits, including developmental delay and neurological/intellectual impairments
    • facial feature anomalies, including microcephaly
  • Fetal Alcohol Effects (FAE)
    • cardiac abnormalities
    • neonatal irritability and hypotonia
    • hyperactivity
    • genitourinary abnormalities
    • skeletal and muscular abnormalities
    • ocular problems
    • hemangiomas
  • No effect

Guidelines for Medical Withdrawal From Alcohol

Procedures at the Time of Admission

1 Obtain a detailed health history, including alcohol and other drug use and arrangements for prenatal care.

2 Conduct a comprehensive physical examination, including weight, vital signs, and an obstetrical evaluation.

3 Obtain laboratory tests, including: a) Initial blood workup that includes, but is not limited to

  • Blood group, Rh factor determination, and antibody screen
  • Serological test for syphilis
  • Hepatitis B and C screens
  • Complete blood count with indices
b) Other initial laboratory tests that include, but are not limited to
  • Cervical cytology smear (Pap smear), unless the provider has results of a test performed within the past 3 months
  • Cervical culture for gonorrhea
  • Urine screen for urinary tract infection, kidney disease, protein, and glucose
  • Chlamydia screen

4 Obtain purified protein derivative of tuberculin (PPD) test with antigen panel.

5 Obtain urine and/or blood toxicologies (see Urine Toxicology Considerations).

6 Provide for HIV antibody counseling and testing.

7 Obtain baseline sonogram if appropriate.

Dosing Strategy

1 Evaluate the pattern, frequency, and amount of alcohol and other drug use.

2 Obtain a detailed history of alcohol and other drug use within the past 24 hours and of any previous alcohol withdrawal reaction.

3 Begin initial treatment with thiamine, folic acid, and prenatal iron and vitamins. Obtain laboratory tests listed above, including CBC, electrolytes, and magnesium level and, when indicated, obtain an electrocardiogram (EKG).

4 Obtain an initial blood alcohol level to determine

  • Extent of intoxication at admission
  • Safe time to begin medication
  • Expected time for full withdrawal to begin. The usual rate of elimination of alcohol from a healthy alcohol dependent person is 30 mg/dl/hr. This rate may be increased during pregnancy.

5 Provide for nonpharmacological interventions designed to

  • Reduce stimuli
  • Maintain hydration
  • Maintain reality orientation
  • Provide reassurance and positive reinforcement
  • Provide nutritional support
  • Maintain physical comfort
  • Maintain body temperature
  • Encourage sleep and rest

6 Follow withdrawal schedule. Programs use different drugs to withdraw patients from alcohol. Drugs used include chlordiazepoxide, phenobarbital, and diazepam.

  • Typical withdrawal schedules using chlordiaze-poxide include 25 to 50 mg 4 times a day for the first 2 days, decreasing gradually to 10 mg 4 times a day for days 8 through 10.
  • Typical withdrawal schedules using phenobarbital include 15 to 60 mg by mouth every 4 to 6 hours as needed for the first 2 days, decreasing gradually to 15 mg by the 4th day.
  • Typical withdrawal schedules using diazepam include 10 mg 4 times a day; 10 mg every 2 hours as needed for withdrawal symptoms with a maximum of 150 mg/24 hours; decreasing gradually at a rate of 20 to 25 percent over approximately 5 days.
  • The loading dose protocol with diazepam is accomplished with doses given according to withdrawal symptomatology. When withdrawal symptoms are stabilized, the long half-life of diazepam alleviates the need for further medication in most cases.

7 Monitor for signs and symptoms of alcohol withdrawal syndrome (AWS). The use of withdrawal assessment scales can be valuable in determining the need for further medication. Monitor for the following:

  • Vital signs (temperature, blood pressure, pulse)
  • Delirium (orientation)
  • Wernicke's encephalopathy (nystagmus)
  • Psychosis (hallucinations, inappropriate thinking)
  • Irritability (tremors, increased reflexes)
  • Increased autonomic reflexes (goosebumps, sweating)
  • Fetal well-being (fetal heart tones, sonograms, or Non-Stress Test) as appropriate for gestational age

8 Reduce medication dose if the patient shows signs of oversedation.

9 Provide for positive social support for the patient to help manage stress.

10 Discharge the patient after medical withdrawal to the care of a case manager for continuing treatment and prenatal care.

 



NCADI Live Help
Send this Page to a Friend E-mail this Page
Printer Friendly Version Print this Page
Join the eNetwork Join the eNetwork
Contact Us Contact Us
Link to Us Link to Us
Home Home

Fetal Alcohol Syndrome (new window)

Multimedia
 
Initiatives  |   Funding  |   Home
U.S. Department of Human and Health Services U.S. Department of Health and Human Services
Substance Abuse and Mental Health Services Administration
Center for Mental Health Services
Center for Substance Abuse Prevention
Center for Substance Abuse Treatment
 
National Clearinghouse for Alcohol and Drug Information
About Us | Privacy | Accessibility | Disclaimer | Site Map | Awards |Customer Service
SAMHSA Home | Freedom of Information Act | Department of Health and Human Services | The White House | USA.gov